BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37105210)

  • 21. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Duarte RF; Canals C; Onida F; Gabriel IH; Arranz R; Arcese W; Ferrant A; Kobbe G; Narni F; Deliliers GL; Olavarría E; Schmitz N; Sureda A
    J Clin Oncol; 2010 Oct; 28(29):4492-9. PubMed ID: 20697072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
    Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
    Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Goyal A; O'Leary D; Foss F
    Bone Marrow Transplant; 2024 Jan; 59(1):41-51. PubMed ID: 37853164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
    Atilla PA; Atilla E
    Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of Cutaneous T-Cell Lymphomas.
    Larocca CA; LeBoeuf NR
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):669-686. PubMed ID: 31229162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
    Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
    Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
    Parker SR; Bethaney JV
    G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome.
    Virmani P; Zain J; Rosen ST; Myskowski PL; Querfeld C
    Dermatol Clin; 2015 Oct; 33(4):807-18. PubMed ID: 26433851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.
    Wu PA; Kim YH; Lavori PW; Hoppe RT; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):982-90. PubMed ID: 19589488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation in mycosis fungoides.
    Atalla A; Hallack Neto AE; Siqueira DB; Toledo GC
    An Bras Dermatol; 2013; 88(6 Suppl 1):216-9. PubMed ID: 24346924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; A Wilcox R
    Am J Hematol; 2021 Oct; 96(10):1313-1328. PubMed ID: 34297414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
    Novelli S; Martín A; Sánchez JJ; Espeso M; Mozos A; Briones J
    Eur J Dermatol; 2020 Aug; 30(4):397-403. PubMed ID: 32815814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapies for cutaneous T-cell lymphomas.
    Kaplan JB; Guitart J; Giles FJ
    Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.